Table 2 Study characteristics – part 2
Author, yr location | n | Gender M/F | Age mean (SD) yrs | OM | Setting (n)% / method of pt selection | Cancer type (n)% | Cancer stage (n)% | Cancer treatment at baseline time-point (n)% |
|---|---|---|---|---|---|---|---|---|
Functional capacity | Â | Â | Â | Â | Â | Â | Â | Â |
Jones 2012 USA [40] | 118 | 71/47 | 61 ± 10 | 6MWT | Health system / consecutive | NSCLC | IIIB, IV, recurrent IV | Chemo (70) 59%; RT (10) 8%; post-op (27) 23%; post-chemo (55) 47%; post-RT (54) 46% |
Pancieri 2010 Brazil [22] | 40 | 22/18 | 48 ± 16 | 6MWT; SCT | Hospital / consecutive | NSCLC (33) 82.5%; other LC (2) 5%; benign (5) 12.5% | NR | Pre-op LR |
Kasymjanova 2009 Canada [25] | 64 | 29/35 | 62.0 ± 10.8 | 6MWT | Outpt clinic / consecutive | NSCLC | III (8) 12%; IV (56) 87% | Pre-chemo |
53 | 28/25 | 64 (range 45–81) | 6MWT | Hospital/ sample part of larger prospective trial | NSCLC (39) 74%; SCLC (12) 23%; meso (1) 2%; lung met (1) 2% | NSCLC only: I – II (4) 8%; III-IV (41) 77%; recurrent (8) 15% | Pre- RT (17) 32%; pre-chemo-RT (36) 68%; prior chemo (33) 62%; | |
Saad 2007 Brazil [24] | 36 | 20/16 | Median 55.5 ± 13.4 | 6MWT | Hospital / consecutive | NSCLC (26) 72%; lung met (8) 22%; sarcoma (2) 6% | NR | Pre-op LR |
Parsons 2003 Canada [39] | 70 | 40/30 | 65 (range 29–83) | 6MWT SCT | Hospital / convenience | NSCLC (55) 79%; pulmonary met (11) 16%; meso (2) 3%; benign (2) 3% | NR | Pre-op LR |
Pierce 1994 Australia [23] | 54 | 54/0 | 67 ± 7 | 6MWT | Hospital / consecutive | LC (including NSCLC) | NR | Pre-op LR |
Holden 1992 USA [41] | 16 | 13/3 | 68 ± 9.3 | 6MWT; SCT | Hospital | NSCLC (15) 94%; SCLC (1) 6% | I (10) 62%; II (3) 19%; III (2) 12%; IV (1) 6% | Pre-op LR |
England 2012 UK [44] | 41 | 21/20 | 64 ± 8 | ISWT | Outpt clinic | NSCLC (26) 63%; meso (11) 27%; SCLC (4) 10% | Local (21) 51%; advanced (20); 49% | Post pall-chemo (26) 63%; post pall-RT (10) 24%; post-RT (1) 2% |
Win 2006 UK [30] | 125 | 81/44 | 68.8 ± 7.7 | ISWT | Consecutive | NSCLC | NR | Pre-op LR |
Win 2004 UK [64] | 111 | 71/40 | 69 (range 42–85) | ISWT | Outpt clinic | NSCLC (107) 96%; miscellaneous (4) 4% | I-IIIA | Pre-op LR |
Brunelli 2012 Italy [43] | 282 | 218/64 | 68.0 ± 9.8 | SCT | Tertiary referral centre / consecutive | NSCLC | I (118) 42%; other (164) 58% | Pre-op LR |
Brunelli 2010 Italy [31] | 109 | 83/26 | 66.6 ± 11.1 | SCT | Tertiary referral centre / consecutive | NSCLC | NR | Pre-op LR |
Brunelli 2008a Italy [34] | 536 | 426/110 | 67 ± 9 | SCT | Tertiary referral centre / consecutive | NSCLC | I (206) 38% ; > I (330) 62% | Pre-op LR (536) 100%; chemo (56) 10% |
Brunelli 2008b Italy [33] | 640 | NR | 66.7 ± 9.3 | SCT | Tertiary referral centre / consecutive | NSCLC | NR | Pre-op LR (640) 100%; neoadjuvant chemo (100) 16% |
Koegelenberg 2008 South Africa [29] | 44 | 31/13 | 47.6 ± 12.5 | SCT | Tertiary referral centre / consecutive | NSCLC (13) 29%; benign (31) 70% | NR | Pre-op LR |
Nikolic 2008 Croatia [36] | 101 | 82/19 | 61.1 ± 8.4 | SCT | Hospital / consecutive | NSCLC | NR | Pre-op LR |
Brunelli 2007 Italy [20] | 200 | NR | 66.8 ± 9.1 | SCT | Tertiary referral centre / consecutive | NSCLC | NR | Pre-op LR (200) 100%; neoadjuvant chemo (19) 9.5% |
Toker 2007 Turkey [37] | 150 | 127/23 | 59.3 ± 10.3 (gp 1) 60.7 ± 10.9 (gp 2) | SCT | University hospital / consecutive | NSCLC | NR | Pre-op LR |
Brunelli 2005 Italy [42] | 391 | 309/82 | 69.1 ± 8.3 (gp 1) 67.0 ± 9.0 (gp 2) | SCT | Tertiary referral centre / consecutive | NSCLC | NR | Pre-op LR |
Brunelli 2004 Italy [35] | 109 | NR | 75.2 ± 3.0 | SCT | Tertiary referral centre / consecutive | NSCLC | I (23) 21% ; > I (86) 79% | Pre-op lobectomy |
Brunelli 2003 Italy [21] | 227 | NR | 66.4 ± 9.1 (gp 1) 66.8 ± 8.1 (gp 2) | SCT | Tertiary referral centre / consecutive | NSCLC | NR | Pre-op LR |
Brunelli 2002 Italy [32] | 160 | 128/32 | 66.2 ± 9.6 | SCT | Tertiary referral centre / consecutive | NSCLC | NR | Pre-op LR |
Pate 1996 USA [38] | 12 | 10/2 | 63.6 ± 4.9 | SCT | Three university hospitals / consecutive | NSCLC (7) 58%; NR (5) 42% | I (5) 42%; III (2) 17%; NR (5) 42% | Pre-op LR |
Physical activity | Â | Â | Â | Â | Â | Â | Â | Â |
Maddocks 2012 UK [47] | 84 | 54/30 | 66 ± 9 | Acc | Outpt clinic | NSCLC (71) 84%; SCLC (8) 9%; meso (5) 6% | IIIB (43) 51%; IV (41) 49% | Palliative Rx |
84 | 65/19 | 62 (range 40–94) | Acc | Hospital inpt (42) 50%; home (42) 50% | NSCLC | II (1) 1%; III (18) 21%; IV (65) 77% | Pre-chemo (84) 100%; prior Rx (31) 37% | |
Maddocks 2010 UK [46] | 60 | 40/20 | 68 ± 9 | Acc | Outpt clinic | NSCLC (53) 88%: meso (5) 8%; GI (2) 3% | Local (35) 58%; advanced (25) 42% | NR |
Novoa 2011 Spain [51] | 38 | 30/8 | 62.8 ± 10.1 | Pedom | Output clinic / consecutive | NSCLC | NR | Pre-op LR |
Muscle strength | Â | Â | Â | Â | Â | Â | Â | Â |
Trutschnigg 2008 Canada [28] | 74 | 48/26 | 61.5 ± 13.1 | HGD | Hospital and laboratory | NSCLC; GI | Advanced | NR |
Brown 2005 UK [53] | 53 | 30/23 | Median 64 (range 43–81) | HGD CST | Palliative care centre x 2 and hospital | Gp1: healthy controls (15) 100% Gp2: cancer: NSCLC (29) 76%; SCLC (6) 16%; no histology LC (3) 8% | Locally advanced (20) 53%; IV (18) 47% | NR |
Knols 2002 Switzerland [52] | 40 | 27/13 | 49.4 ± 14.8 | HHD+ pulley | Hospital inpt / convenience | NSCLC (7) 17.5%; other LC (3) 7.5%; haem (20) 50%; sarcoma (5) 12.5%; seminoma (3) 7.5%; other (2) 5% | I-IV | Chemo |